Cardiology News and Research

Latest Cardiology News and Research

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and sustain control of their blood sugar levels. The new insulin delivery device was launched today in conjunction with the 20th World Diabetes Congress being held in Montreal, Quebec, making Canada one of the first countries worldwide to launch this state-of-the-art pen.

20 Oct 2009

NIH funded regeneration research to be presented at Society for Neuroscience annual meeting

Biologists long have marveled at the ability of some animals to re-grow lost body parts. Newts, for example, can lose a leg and grow a new one identical to the original. Zebrafish can re-grow fins.

20 Oct 2009

Humans are still evolving, says study

Although advances in medical care have improved standards of living over time, humans aren't entirely sheltered from the forces of natural selection, a new study shows.

20 Oct 2009

Diabetes represents a global health threat

The International Diabetes Federation (IDF) released new data today showing that a staggering 285 million people worldwide have diabetes.

20 Oct 2009

Third-quarter financial results of Boston Scientific announced

Boston Scientific Corporation today announced financial results for the third quarter ended September 30, 2009, as well as guidance for net sales and earnings per share (EPS) for the fourth quarter and full year 2009.

20 Oct 2009

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.

20 Oct 2009

FDA approves new oral medication for renal cell carcinoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

20 Oct 2009

Scientists find cause for lupuslike disease in mice

Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease.

19 Oct 2009

More details emerging on health reform's proposed changes to Medicare

The Dallas Morning News reports on some of health reform's proposed changes to Medicare and local consumer reactions. "The 10.4 million beneficiaries with private insurers' Medicare Advantage plans will still get coverage at least comparable to regular Medicare, but some will see fewer extra benefits or higher out-of-pocket costs. For most of Medicare's 45 million beneficiaries, an overhaul will improve coverage by beefing up drug benefits, preserving access to physicians, paying for more preventive care and putting Medicare on firmer financial footing."

19 Oct 2009

FDA approves Boehringer Ingelheim's MICARDIS for the reduction of risk of heart attack

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.

19 Oct 2009

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace’), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.

19 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

PLC Systems' RenalGuard to be utilized in a live case transmission at the GISE 2009 conference

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that its RenalGuard System(TM) will be utilized as part of a live case transmission from the Clinica Mediterranea, Naples, Italy, to the 30th Congresso Nazionale della Societa' Italiana di Cardiologia Invasiva (GISE) during the conference.

19 Oct 2009

Metabolic master switch sets the biological clock in body tissues

Our body's activity levels fall and rise to the beat of our internal drums-the 24-hour cycles that govern fundamental physiological functions, from sleeping and feeding patterns to the energy available to our cells. Whereas the master clock in the brain is set by light, the pacemakers in peripheral organs are set by food availability. The underlying molecular mechanism was unknown.

19 Oct 2009

Chinese SFDA approves China Medical Technologies' SPR System

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").

19 Oct 2009

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

AstraZeneca today announced the U.S. Food and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.

19 Oct 2009

Anti-clotting drug may cause problems for elderly trauma patients: Study

A common drug used for preventing heart attacks and blood clots may also cause problems for individuals who suffer some form of trauma, particularly elderly patients, according to a study presented today at the 2009 Clinical Congress of the American College of Surgeons.

19 Oct 2009

New mathematical model for rapid and accurate diagnoses of AHF

Researchers at St. Michael's Hospital have developed the first mathematical model in cardiology and emergency medicine to more quickly and reliably diagnose acute heart failure (AHF) in emergency room patients

19 Oct 2009

UNC scientists receive GO grant to study the human genome blueprint

Ever since the first genome sequence was published in 2001, scientists have been working to figure out what the sequence means. An analogy is walking across a desert and finding a large book in a language you don't know, then trying to figure out what the book is saying.

19 Oct 2009

Readmission of elderly patients after colectomy strongly linked with mortality: Study

Readmission to a hospital after standard surgical treatment for colon cancer is far more common than suspected for elderly patients according to researchers who presented their findings at the 2009 Clinical Congress of the American College of Surgeons. Results from the first study to determine nationwide readmission rates following colectomy [surgical removal of malignant disease and part of the colon] in the Medicare population revealed that nearly one in nine patients over the age of 65 was readmitted within 30 days.

19 Oct 2009

Cardiology News and Research

Latest Cardiology News and Research

Health Canada approves new Lantus ClikSTAR reusable insulin pen

NIH funded regeneration research to be presented at Society for Neuroscience annual meeting

Humans are still evolving, says study

Diabetes represents a global health threat

Third-quarter financial results of Boston Scientific announced

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

FDA approves new oral medication for renal cell carcinoma

Scientists find cause for lupuslike disease in mice

More details emerging on health reform's proposed changes to Medicare

FDA approves Boehringer Ingelheim's MICARDIS for the reduction of risk of heart attack

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

PLC Systems' RenalGuard to be utilized in a live case transmission at the GISE 2009 conference

Metabolic master switch sets the biological clock in body tissues

Chinese SFDA approves China Medical Technologies' SPR System

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

Anti-clotting drug may cause problems for elderly trauma patients: Study

New mathematical model for rapid and accurate diagnoses of AHF

UNC scientists receive GO grant to study the human genome blueprint

Readmission of elderly patients after colectomy strongly linked with mortality: Study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cardiology News and Research

Latest Cardiology News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in